PSMA3 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PSMA3 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PSMA3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PSMA3</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=PSMA3" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/huntington" style="color:#ef9a9a">Huntington</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">58 edges</a></td>
</tr>
</table>
Psma3 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
...
PSMA3 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PSMA3 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PSMA3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PSMA3</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=PSMA3" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/huntington" style="color:#ef9a9a">Huntington</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">58 edges</a></td>
</tr>
</table>
Psma3 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
PSMA3 (Proteasome Subunit Alpha Type 3) is a critical component of the 20S proteasome core particle, the proteolytic machinery responsible for degrading ubiquitin-tagged proteins. Also known as proteasome subunit alpha type-3 or HC5, this protein plays an essential role in cellular protein homeostasis, antigen processing, and the clearance of misfolded proteins that accumulate in neurodegenerative diseases. [@ciechanover2015]
The proteasome represents a fundamental defense against proteotoxic stress, and dysfunction of this system is increasingly recognized as a key contributor to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and other neurodegenerative disorders. [@ding2019]
Protein Structure
Primary Structure
PSMA3 consists of 255 amino acids with a molecular weight of approximately 28.1 kDa. The protein contains: [@tai2012]
- N-terminal threonine residue (Thr1): The nucleophilic residue that serves as the catalytic site for proteolysis
- Alpha-helical domains: Contributing to the structural integrity of the proteasome α-ring
- Hinge regions: Allowing conformational flexibility essential for gate opening
Quaternary Structure
PSMA3 is one of seven α-subunits (PSMA1-7) that form the outer α-ring of the 20S proteasome. This heptameric ring creates a gated channel controlling substrate access to the proteolytic chamber: [@bedford2011]
Structural Features
N-terminal nucleophile (Ntn) hydrolase fold: Common to all proteasome α and β subunits
H6 helix: Important for subunit interactions within the α-ring
Propeptide: Cleaved during maturation to expose the catalytic threonineNormal Cellular Functions
Ubiquitin-Proteasome System (UPS)
The [UPS](/mechanisms/ubiquitin-proteasome-system) is the primary mechanism for targeted protein degradation in eukaryotic cells: [@kakkar2014]
Ubiquitination: E1/E2/E3 enzymes conjugate ubiquitin chains to target proteins
Recognition: The 19S regulatory particle binds ubiquitinated substrates
Degradation: Substrates are unfolded and translocated into the 20S core
Proteolysis: Peptide bonds are cleaved by the β-subunit catalytic sitesProteasome Assembly
PSMA3 is essential for proper 20S proteasome assembly: [@lim2021]
- α-ring formation: PSMA1-7 assemble as a pre-complex
- β-subunit incorporation: β-catalytic subunits are incorporated
- Maturation: Autocatalytic cleavage removes propeptides
- Active proteasome: Mature particle is proteolytically active
Substrate Recognition
The α-ring, including PSMA3, controls substrate entry through: [@mckinnon2022]
- Gate opening: Conformational changes allow substrate entry
- Subunit-specific interactions: Different α-subunits influence substrate specificity
- Regulatory particle binding: 19S caps facilitate substrate engagement
Role in Neurodegenerative Diseases
Alzheimer's Disease
Proteasome function is impaired in AD brain: [@chen2023]
- PSMA3 levels: Decreased in prefrontal [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
- Mechanisms: Oxidative stress, phosphorylation, and aggregation all impair proteasome activity
- Consequence: Accumulation of damaged proteins and aggregates
- [Tau](/proteins/tau) pathology: Proteasome impairment contributes to tau accumulation
- Amyloid interaction: [Aβ](/proteins/amyloid-beta) can directly inhibit proteasome activity
Parkinson's Disease
The proteasome is critically involved in PD: [@bingol2014]
- [α-Synuclein](/proteins/alpha-synuclein) clearance: Proteasome degrades monomeric α-synuclein
- Genetic links: PARKIN (E3 ligase) mutations cause familial PD
- Lewy bodies: Contain ubiquitinated proteins that escape degradation
- Substantia nigra: Particularly vulnerable to proteasome dysfunction
- Proteasome inhibitors: Induce dopaminergic neuron death
Amyotrophic Lateral Sclerosis
ALS features prominent proteasome dysfunction:
- [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology: Ubiquitinated TDP-43 inclusions
- Mutant SOD1: Disrupts proteasome assembly
- [C9orf72](/entities/c9orf72): Hexanucleotide repeats affect proteasome function
- Motor neuron vulnerability: High protein turnover makes motor [neurons](/entities/neurons) susceptible
Huntington's Disease
Proteasome impairment contributes to HD:
- Mutant [huntingtin](/proteins/huntingtin): Impairs proteasome function
- Aggregate clearance: Failed degradation leads to inclusion formation
- Transcriptional dysregulation: Proteasome affects transcription factor levels
Molecular Mechanisms of Dysfunction
Oxidative Modification
[Reactive oxygen species](/entities/reactive-oxygen-species) (ROS) can:
- Oxidize catalytic threonine
- Modify PSMA3 structure
- Reduce proteasome assembly
- Impair substrate recognition
Phosphorylation
Kinases can modulate proteasome activity:
- PKA: Phosphorylation can enhance activity
- CaMKII: Regulates proteasome localization
- GSK3β: Linked to tau-proteasome interactions
Aggregation
Protein aggregates can:
- Sequester proteasome subunits
- Block substrate entry
- Titrate available proteasomes
- Create a feed-forward cycle of dysfunction
Therapeutic Implications
Proteasome Activators
Drug development focuses on:
- Natural compounds: Polyphenols can enhance proteasome activity
- Small molecules: Novel activators in development
- Gene therapy: Increasing proteasome subunit expression
Combination Approaches
Rational combinations include:
- UPS enhancers + aggregation inhibitors: Dual mechanisms
- [Autophagy](/entities/autophagy) induction: Complementary degradation pathway
- Antioxidants: Protect proteasome from oxidative damage
Biomarker Potential
Proteasome measurements may serve as:
- Disease biomarkers: In CSF or blood
- Therapeutic monitoring: Response to treatment
- Prognostic indicators: Disease progression markers
Research Methods
Detection Techniques
- Western blot: Protein level quantification
- Immunohistochemistry: Localization in tissue
- Activity assays: Fluorogenic substrate cleavage
- Proteomics: Global proteasome complex analysis
Functional Studies
- CRISPR-Cas9: Genetic manipulation of PSMA3
- siRNA knockdown: Acute proteasome impairment
- Overexpression: Determining overexpression effects
- iPSC models: Patient-derived neurons
Summary
PSMA3 represents a critical node in cellular protein homeostasis. As a core component of the 20S proteasome α-ring, it is essential for gate regulation and substrate entry. Proteasome dysfunction is increasingly recognized as a common feature of neurodegenerative diseases, making PSMA3 and related proteins attractive therapeutic targets. Understanding the precise mechanisms of proteasome impairment and developing strategies to enhance proteasome function remain active areas of research with significant clinical implications.
See Also
- [Neurodegeneration](/diseases/neurodegeneration) — General mechanisms
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
Overview
Psma3 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Psma3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Groll M et al., Structure of 20S proteasome (1997) (1997)](https://pubmed.ncbi.nlm.nih.gov/9370352/)
[Unknown, Ciechanover A, The ubiquitin-proteasome system (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26542804/)
[Ding Q et al., Proteasome in neurodegeneration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30895141/)
[Tai HC et al., Proteasome dysfunction in neurodegeneration (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22508678/)
[Bedford L et al., Protein aggregates in neurodegeneration (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21315561/)
[Kakkar V et al., Proteostasis and neurodegeneration (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25108232/)
[Lim KH et al., Proteasome activity in Alzheimer's disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34152667/)
[McKinnon C et al., Alpha-synuclein and proteasome (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35903892/)
[Chen T et al., Proteasome activators for neurodegenerative disease (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37245618/)
[Unknown, Bingol B, Autophagy and proteasome crosstalk (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25040165/)